Identifying metabolic features of colorectal cancer liability using Mendelian randomization

Caroline J. Bull^{1,2,3*}, Emma Hazelwood^{1,2*}, Joshua A. Bell^{1,2}, Vanessa Y. Tan^{1,2}, Andrei-Emil Constantinescu^{1,2}, Maria Carolina Borges^{1,2}, Danny N. Legge³, Kimberly Burrows^{1,2}, Jeroen R. Huyghe⁴, Hermann Brenner^{5,6,7}, Sergi Castellví-Bel⁸, Andrew T Chan^{9,10,11,12,13,14}, Sun-Seog Kweon^{15,16}, Loic Le Marchand¹⁷, Li Li¹⁸, Iona Cheng^{19,20}, Rish K. Pai²¹, Jane C. Figueiredo²², Neil Murphy²³, Marc J. Gunter^{23,24}, Nicholas J. Timpson^{1,2}, Emma E. Vincent^{1,2,3}.

¹ MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK

² Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

³ Translational Health Sciences, Bristol Medical School, University of Bristol, UK

⁴ Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
 ⁵ Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany

⁶ Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany

⁷ German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany

⁸ Gastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain

⁹ Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

¹⁰ Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA

¹¹ Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

¹² Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA

¹³ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA

¹⁴ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA

¹⁵ Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Korea

¹⁶ Jeonnam Regional Cancer Center, Chonnam National University Hwasun Hospital, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Hwasun, Korea

¹⁷ University of Hawaii Cancer Center, Honolulu, Hawaii, USA

¹⁸ Department of Family Medicine, University of Virginia, Charlottesville, Virginia, USA

¹⁹ Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA

²⁰ University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, San Francisco, California, USA

²¹ Department of Pathology and Laboratory Medicine, Mayo Clinic, Arizona, Scottsdale, Arizona, USA

²² Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA

²³ Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France

²⁴ Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom

* These authors contributed equally and are joint first authors.

Corresponding author: Emma E. Vincent, emma.vincent@bristol.ac.uk

Abstract

Background: Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival.

Methods: To investigate whether changes in circulating metabolites characterise the early stages of colorectal cancer (CRC) development, we examined associations between a genetic risk score (GRS) associated with CRC liability (72 single nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N=6,221). Linear regression models were applied to examine associations between genetic liability to colorectal cancer and circulating metabolites measured in the same individuals at age 8, 16, 18 and 25 years.

Results: The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P<0.05 across all time points, particularly with higher fatty acids and very-low- and lowdensity lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N=118,466, median age 58y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward)

MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk.

Conclusions: These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism, and suggest that fatty acids may play an important role in CRC development.

Funding: This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, the Wellcome Trust, the Medical Research Council, Diabetes UK, the University of Bristol NIHR Biomedical Research Centre, and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol - http://www.bristol.ac.uk/acrc/.

Keywords: Colorectal cancer; Metabolism; Genetics; NMR; Epidemiology; Mendelian randomization; ALSPAC; UK Biobank; GECCO; CCTS; CCFR

1 Introduction

2

3 Colorectal cancer (CRC) is the third most frequently diagnosed cancer worldwide and the fourth 4 most common cause of death from cancer.^{1,2} There is a genetic component to risk of the disease, 5 which is thought to explain up to 35% of variability in CRC risk.^{3–5} In addition, modifiable lifestyle 6 factors, including obesity, consumption of processed meat, and alcohol are thought to increase 7 CRC risk.^{2,6–9} However, the underlying biological pathways remain unclear, which limits targeted 8 prevention strategies. Whilst CRC has higher mortality rates when diagnosed at later stages, 9 early-stage CRC or precancerous lesions are largely treatable, meaning colorectal cancer screening programmes have the potential to be highly effective.^{10,11} Due to the lack of known 10 11 predictive biomarkers for CRC, wide-scale screening (if implemented at all) is expensive and often 12 targeted crudely by age range. Identifying biomarkers predictive of CRC, or with causal roles in 13 disease development, is therefore vital.

14

15 One potential source of biomarkers for CRC risk is the circulating metabolome, which offers a 16 dynamic insight into cellular processes and disease states. It is increasingly clear from 17 mechanistic studies that both systemic and intracellular tumour metabolism play an important role 18 in CRC development and progression.^{12,13} Interestingly, several major risk factors for CRC are 19 known to have profound effects on metabolism.¹⁴ For instance, obesity has been shown via 20 conventional observational and Mendelian randomization (MR) analyses to strongly alter 21 circulating metabolite levels.^{9,15–17} This suggests that the circulating metabolome may play a 22 mediating role in the relationship between at least some common risk factors, such as obesity, 23 and CRC – or at least might be a useful biomarker for disease or intermediates thereof. In 24 particular, previous work has highlighted polyunsaturated fatty acids (PUFA) as potentially having 25 a role in colorectal cancer development. The term PUFA includes omega-3 and -6 fatty acids. 26 Recent MR work has highlighted a possible link between PUFAs, in particular omega 6 PUFAs, 27 and colorectal cancer risk.¹⁸ Further investigating the relationship between CRC and circulating 28 metabolites may therefore provide powerful insights into the causal pathways underlying disease 29 risk, or alternatively may be valuable in prediction and early diagnosis.

30

31 MR is a genetic epidemiological approach used to evaluate causal relationships between 32 traits.^{19,20} This method uses genetic variation as a proxy measure for traits in an instrumental 33 variable framework to assess the causal relevance of the traits in disease development. As 34 germline genetic variants are theoretically randomised between generations and fixed at

35 conception, this approach should be less prone to bias and confounding than conventional 36 analyses undertaken in an observational context. Conventionally, MR is used to investigate the 37 effect of an exposure on a disease outcome. In reverse MR, genetic instruments proxy the 38 association between liability to a disease and other traits.²¹ This approach can identify biomarkers 39 which cause the disease, are predictive for the disease, or have diagnostic potential.²¹ Given the 40 suspected importance of the circulating metabolome in CRC development, employing both 41 reverse MR and conventional forward MR for metabolites in the same study may be an efficient 42 approach for revealing causal and predictive biomarkers for CRC. Although previous 43 observational studies have investigated associations between the circulating metabolome and 44 CRC risk, these studies may have been influenced by confounding bias which should be less relevant to MR analyses.^{22–31} Additionally, these studies focussed on adults, who commonly take 45 46 medications which may confound metabolite associations, further complicating interpretations.

47

Here, we applied a reverse MR framework to identify circulating metabolites which are associated with CRC liability across different stages of the early life course (spanning childhood to young adulthood, when use of medications and CRC are both rare) using data from a birth cohort study. We then attempted to replicate these results using reverse two-sample MR in an independent cohort of middle-aged adults (UK Biobank). We then performed conventional 'forward' MR of metabolites onto CRC risk using large-scale cancer consortia data to identify metabolites which may have a causal role in CRC development.

- 55
- 56
- 57
- 58 Methods
- 59

61

This study uses data from 2 cohort studies: the Avon Longitudinal Study of Parents and Children (ALSPAC) offspring (generation 1) cohort (individual-level data) and the UK Biobank cohort (summary-level data); plus summary-level data from a genome-wide association study (GWAS) meta-analysis of CRC comprising the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), Colorectal Transdisciplinary Study (CORECT), and Colon Cancer Family Registry (CCFR).

68

⁶⁰ Study populations

69 ALSPAC is a population-based birth cohort study in which 14,541 pregnant women with an 70 expected delivery date between 1 April 1991 and 31 December 1992 were recruited from the 71 former Avon County of southwest England.³² Since then, 13,988 offspring alive at one year have been followed repeatedly with questionnaire- and clinic-based assessments.^{33,34} Sufficient 72 73 information was available on 6,221 of these individuals to be included in our analysis, as 74 metabolomics was not performed for all individuals in the ALSPAC study. Study data were 75 collected and managed using REDCap electronic data capture tools hosted at the University of 76 Bristol.³⁵ REDCap (Research Electronic Data Capture) is a secure, web-based software platform 77 designed to support data capture for research studies. Offspring genotype was assessed using 78 the Illumina HumanHap550 quad chip platform. Quality control measures included exclusion of 79 participants with sex mismatch, minimal or excessive heterozygosity, disproportionately missing 80 data, insufficient sample replication, cryptic relatedness, and non-European ancestry. Imputation 81 was performed using the Haplotype Reference Consortium (HRC) panel. Offspring were 82 considered for the current analyses if they had no older siblings in ALSPAC (203 excluded) and 83 were of white ethnicity (based on reports by parents, 604 excluded) to reduce the potential for 84 confounding by genotype. The study website contains details of all available data through a fully 85 searchable data dictionary and variable search tool 86 (http://www.bristol.ac.uk/alspac/researchers/our-data/).

87

UK Biobank is a population-based cohort study based in 22 centres across the UK.³⁶ The cohort 88 89 is made up of around 500,000 adults aged 40-80 years old, who were enrolled between 2006 and 90 2010. Genotyping data is available for 488,377 participants.³⁷ Participants were genotyped using 91 one of two arrays - either the Applied Biosystems UK BiLEVE Axiom Array by Affymetrix (now 92 part of Thermo Fisher Scientific), or the closely related Applied Biosystems UK Biobank Axiom 93 Array. Approaches based on Principal Component Analysis (PCA) were used to account for 94 population structure. Individuals were excluded: if reported sex differed from inferred sex based 95 on genotyping data; if they had sex chromosome karyotypes which were not XX or XY; if they 96 were outliers in terms of heterozygosity and missing rates; or if they had high relatedness to 97 another participant. Multiallelic SNPs or those with a minor allele frequency of below 1% were 98 removed. Imputation was performed using the UK10K haplotype and HRC reference panels. 99

100 The GWAS meta-analysis for CRC included up to 52,775 cases and 45,940 controls.^{38,39} This 101 sample excluded cases and controls from UK Biobank to avoid potential bias due to sample

102 overlap which may be problematic in MR analyses.⁴⁰ Cases were diagnosed by a physician and 103 recorded overall and by site (colon, 28,736 cases; proximal colon, 14,416 cases; distal colon, 104 12,879 cases; and rectal, 14,150 cases). Colon cancer included proximal colon (any primary 105 tumour arising in the cecum, ascending colon, hepatic flexure, or transverse colon), distal colon 106 (any primary tumour arising in the pleenic flexure, descending colon or sigmoid colon), and colon 107 cases with unspecified site. Rectal cancer included any primary tumour arising in the rectum or 108 rectosigmoid junction.³⁸ Approximately 92% of participants in the overall CRC GWAS were white-109 European (~8% were East Asian). All participants included in site-specific CRC analyses were of 110 European ancestry. Imputation was performed using the Michigan imputation server and HRC 111 r1.0 reference panel. Regression models were further adjusted for age, sex, genotyping platform, 112 and genomic principal components as described previously.³⁸

113

114 Assessment of CRC genetic liability

115

116 Genetic liability to CRC was based on single nucleotide polymorphisms (SNPs) associated with 117 CRC case status at genome-wide significance ($P < 5 \times 10^{-8}$). 108 independent SNPs reported by two major GWAS meta-analyses were eligible for inclusion in a CRC genetic risk score (GRS).^{38,41} 118 119 The set of SNPs was filtered, excluding 36 SNPs that were in linkage disequilibrium based on 120 R²>0.001 using the TwoSampleMR package (SNPs with the lowest P-values were retained).⁴² 121 This left 72 SNPs independently associated with CRC (Supplementary File 1a), 65 of which 122 were available in imputed ALSPAC genotype data post quality control. As GWAS of site-specific 123 CRC have identified marked heterogeneity,⁴³ GRS describing site-specific CRCs were 124 constructed for sensitivity analyses using the same process outlined above. The GRS for colon 125 cancer, rectal cancer, proximal colon cancer and distal colon cancer were comprised of 38, 25, 126 20 and 24 variants, respectively (Supplementary File 1a). For overall CRC and site-specific CRC 127 analyses, sensitivity analyses excluding any SNPs in the FADS cluster (i.e. within the gene 128 regions of FADS1, FADS2, or FADS3) (Supplementary File 1a) were performed given a likely 129 role for these SNPs in influencing circulating metabolite levels directly, in particular via lipid 130 metabolism (i.e., not primarily due to CRC).44-50

131

132 Assessment of circulating metabolites

133

Circulating metabolite measures were drawn from ALSPAC and UK Biobank using the sametargeted metabolomics platform. In ALSPAC, participants provided non-fasting blood samples

136 during a clinic visit while aged approximately 8y, and fasting blood samples from clinic visits while 137 aged approximately 16y, 18y, and 25y. Proton nuclear magnetic resonance (¹H-NMR) 138 spectroscopy was performed on Ethylenediaminetetraacetic acid (EDTA) plasma (stored at or below -70 degrees Celsius pre-processing) to quantify a maximum of 231 metabolites.⁵¹ 139 140 Quantified metabolites included the cholesterol and triglyceride content of lipoprotein particles: 141 the concentrations and diameter/size of these particles; apolipoprotein B and apolipoprotein A-1 142 concentrations; as well as fatty acids and their ratios to total fatty acid concentration, branched 143 chain and aromatic amino acids, glucose and pre-glycaemic factors including lactate and citrate, 144 fluid balance factors including albumin and creatinine, and the inflammatory marker glycoprotein 145 acetyls (GlycA). This metabolomics platform has limited coverage of fatty acids. In UK Biobank, 146 EDTA plasma samples from 117,121 participants, a random subset of the original ~500,000 who 147 provided samples at assessment centres between 2006 and 2013, were analysed between 2019 148 and 2020 for levels of 249 metabolic traits (168 concentrations plus 81 ratios) using the same high-throughput ¹H-NMR platform. Data pre-processing and QC steps are described 149 150 previously.^{51–53} To allow comparability between MR and GRS estimates all metabolite measures 151 were standardised and normalised using rank-based inverse normal transformation. For 152 descriptive purposes in ALSPAC, body mass index (BMI) was calculated at each time point as 153 weight (kg) divided by squared height (m²) based on clinic measures of weight to the nearest 154 0.1 kg using a Tanita scale and height measured in light clothing without shoes to the nearest 0.1 155 cm using a Harpenden stadiometer.

156

157 CRC liability variants were combined into a GRS using PLINK 1.9, specifying the effect (risk 158 raising) allele and coefficient (logOR) with estimates from the CRC GWAS used as external 159 weights.^{38,41} GRSs were calculated as the number of effect alleles (or dosages if imputed) at each 160 SNP (0, 1, or 2) multiplied by its weighting, summing these, and dividing by the total number of 161 SNPs used. Z-scores of GRS variables were calculated to standardize scoring.

162

163 Statistical approach

164

An overview of the study design is presented in **Figure 1**. To estimate the effect of increased genetic liability to CRC on circulating metabolites we conducted a GRS analysis in ALSPAC and reverse two-sample MR analyses in UK Biobank. Estimates were interpreted within a 'reverse MR' framework,⁵⁴ wherein results are taken to reflect 'metabolic features' of CRC liability which could capture causal or predictive metabolite-disease associations. To clarify the direction of metabolite-CRC associations, we additionally performed conventional 'forward' two-sample MR
 analyses to estimate the effect of circulating metabolites on CRC risk using large-scale GWAS
 data on metabolites and CRC.

173

174 1. Associations of CRC liability with circulating metabolites in early life

175

Separate linear regression models with robust standard errors were used to estimate coefficients and 95% confidence intervals for associations of GRSs with each metabolite as a dependent variable measured on the same individuals at age 8y, 16y, 18y, and 25y, adjusted for sex and age at the time of metabolite assessment. To aid interpretations, estimates were multiplied by 0.693 (log_e2) to reflect SD-unit differences in metabolites per doubling of genetic liability to CRC.⁵⁵ The Benjamini-Hochberg method was used to adjust P-values for multiple testing and an adjusted P-value of <0.05 was used as a heuristic for evidence for association given current sample sizes.⁵⁶

183

184 2. Reverse MR of the effects of CRC liability on circulating metabolites in middle adulthood

185

186 "Reverse" MR analyses⁵⁴ were conducted using UK Biobank for outcome datasets in two sample 187 MR to examine the effect of CRC liability on circulating metabolites. SNP-outcome (metabolite) estimates were obtained from a GWAS of metabolites in UK Biobank.^{57,58} Prior to GWAS, all 188 189 metabolite measures were standardised and normalised using rank-based inverse normal 190 transformation. Genetic association data for metabolites were retrieved using the MRC IEU UK Biobank GWAS pipeline.⁵⁹ Full summary statistics are available via the IEU Open GWAS 191 project.^{54,60} Up to 3 statistical methods were used to generate reverse MR estimates of the effect 192 of CRC liability on circulating metabolites using the TwoSampleMR package⁶¹: random-effects 193 194 inverse variance weighted (IVW), weighted-median, and weighted-mode, which each make 195 differing assumptions about directional pleiotropy and SNP heterogeneity.^{62–64} The IVW MR model 196 will produce biased effect estimates in the presence of horizontal pleiotropy, i.e. where one or 197 more genetic variant(s) included in the instrument affect the outcome by a pathway other than 198 through the exposure. In the weighted median model, each genetic variant is weighted according 199 to its distance from the median effect of all genetic variants. Thus, the weighted median model 200 will provide an unbiased estimate when at least 50% of the information in an instrument comes 201 from genetic variants that are not horizontally pleiotropic. The weighted mode model uses a similar approach but weights genetic instruments according to the mean effect. In this model, over 50% of the weight of the genetic instrument can be contributed to by genetic variants which are horizontally pleiotropic, but the most common amount of pleiotropy must be zero (known as the Zero Modal Pleiotropy Assumption (ZEMPA))⁶⁵. As above, estimates were multiplied by 0.693 (log_e2) to reflect SD-unit differences in metabolites per doubling of genetic liability to CRC.⁶⁶

207

208 3. Forward MR of the effects of metabolites on CRC

209

210 Forward MR analyses were conducted using summary statistics from UK Biobank for the same 211 NMR-measured metabolites (SNP-exposure) and from GECCO/CORECT/CCFR as outlined 212 above (SNP-outcome). We identified SNPs that were independently associated (R²<0.001 and 213 P<5x10⁻⁸) with metabolites from a GWAS of 249 metabolites in UK Biobank described above. As 214 before, we used up to 3 statistical methods to generate MR estimates of the effect of circulating 215 metabolites on CRC risk (overall and site-specific): random-effects IVW, weighted-median, and 216 weighted-mode. The Benjamini-Hochberg method was used to adjust P-values for multiple testing 217 and an adjusted P-value of <0.05 was used as a heuristic for nominal evidence for a causal 218 effect.⁵⁶ MR outputs are beta coefficients representing the logOR for CRC per SD higher 219 metabolite, exponentiated to reflect the OR for CRC per SD metabolite.

220

MR analyses were performed in R version 4.0.3.⁶⁷ and GRS analyses in Stata 16.1 (StataCorp,
 College Station, Texas, USA). The ggforestplot R package was used to generate results
 visualisations.⁶⁸

- 224
- 225 Ethics

Written informed consent was obtained for all study participants. Ethical approval was obtained from the ALSPAC Law and Ethics Committee and the local research ethics committee (proposal B3538). Consent for biological samples has been collected in accordance with the Human Tissue Act (2004). Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. Ethics for the CRC GWAS were approved by respective institutional review boards.

- 233
- 234 **Results**

235 236

237 Associations of CRC liability with circulating metabolites in early life

238

239 At the time the ALSPAC blood samples were taken, the mean age of participants was 7.5y 240 (N=4,767), 15.5y (N=2,930), 17.8y (N=2,613), and 24.5y (N=2,559) for the childhood, early 241 adolescence, late adolescence and young adulthood time points respectively. The proportion of 242 participants which were male were 50.5%, 47.4%, 44.5%, and 39.1% and mean BMI was 16.2, 243 21.4, 22.7, and 24.8 kg/m² for each time point respectively. The socio-demographic profile of 244 ALSPAC offspring participants has been reported previously.⁶⁹ Mean and standard deviation (SD) 245 values for metabolites on each measurement occasion in ALSPAC are shown in **Supplementary** 246 File 1b.

247

248 In the GRS analysis, there was no strong evidence of association of CRC liability with metabolites 249 at age 8y (Supplementary File 1c). At age 16y, there was evidence for association with several 250 lipid traits including higher cholesteryl esters to total lipids ratio in large low-density lipoprotein 251 (LDL) (SD change per doubling CRC liability = 0.06, 95% CI = 0.02 to 0.10) and higher cholesterol 252 in very small very low-density lipoprotein (VLDL) (SD change per doubling CRC liability = 0.06, 253 95% CI = 0.03 to 0.10). There was strong evidence for association with several traits at age 18y 254 including higher non-high-density lipoprotein (non-HDL) lipids, e.g., a 1 doubling CRC liability was 255 associated with higher levels of total cholesterol (SD change = 0.05 95% CI = 0.01 to 0.09), VLDL-256 cholesterol (SD change = 0.05, 95% CI = 0.01 to 0.09), LDL-cholesterol (SD change = 0.06, 95% 257 CI = 0.02 to 0.09)), apolipoproteins (apolipoprotein B (SD change = 0.06, 95% CI = 0.02 to 0.09)), 258 and fatty acids (omega-3 (SD change = 0.08, 95% CI = 0.04 to 0.11), docosahexaenoic acid 259 (DHA) (SD change = 0.05, 95% CI = 0.02 to 0.09)) (Supplementary File 1c). Figure 2(-figure 260 supplements 1-6) shows results for all clinically validated metabolites. At age 25y, there was no 261 strong evidence of association of CRC liability with metabolites. In anatomical site-specific 262 analyses, there was strong evidence for association of liability to colon cancer with omega-3 (SD 263 change = 0.07, 95% CI = 0.03 to 0.11) and DHA (SD change = 0.07, 95% CI = 0.03 to 0.10) at 264 age 18y. There was little evidence for any associations at any other CRC site or age 265 (Supplementary File 1c). When SNPs in the FADS cluster gene regions were excluded due to 266 possible horizontal pleiotropy given the role of FADS in lipid metabolism, there was a reduction in 267 strength of evidence for an association of liability to CRC with any metabolite measured, although 268 estimates were in a largely consistent direction with the prior analysis (Supplementary File 1d).

269

- 270 Reverse MR of the effects of CRC liability on circulating metabolites in middle adulthood
- 271

272 All instrument sets from the reverse MR analysis had an F-statistic greater than 10 (minimum F-273 statistic = 36, median = 40), suggesting our analyses did not suffer from weak instrument bias 274 (Supplementary File 1e). There was little evidence of an association of CRC liability (overall or 275 by anatomical site) on any of the circulating metabolites investigated, including when the SNP in 276 the FADS gene region was excluded, based on our pre-determined cut-off of FDR-P < 0.05; 277 however, the direction of effect estimates was largely consistent with those seen in ALSPAC GRS 278 analyses, with higher CRC liability weakly associated with higher non-HDLs, lipoproteins and fatty 279 acid levels (Supplementary File 1f-g). Figure 3(-figure supplements 1-3) shows the results for 280 clinically validated metabolites. In subsite stratified analyses, there was strong evidence for a 281 causal effect of genetic liability to proximal colon cancer on several traits, including total fatty acids 282 (SD change per doubling of liability = 0.02, 95% CI = 0.01 to 0.04) and omega-6 fatty acids (SD 283 change per doubling of liability = 0.03, 95% CI = 0.01 to 0.05).

- 284
- 285 Forward MR for the effects of metabolites on CRC risk
- 286

287 All instrument sets from the forward MR analysis had an F-statistic greater than 10 (minimum F-288 statistic = 54, median = 141), suggesting that our analyses were unlikely to suffer from weak 289 instrument bias (Supplementary File 1h-i). There was strong evidence for an effect of several 290 fatty acid traits on overall CRC risk, including of omega-3 fatty acids (CRC OR = 1.13, 95% CI = 291 1.06 to 1.21), DHA (OR CRC = 1.76, 95% CI = 1.08 to 1.28), ratio of omega-3 fatty acids to total 292 fatty acids (OR CRC = 1.18, 95% CI = 1.11 to 1.25), ratio of DHA to total fatty acids (CRC OR = 293 1.20, 95% CI = 1.10 to 1.31), and ratio of omega-6 fatty acids to omega-3 fatty acids (CRC OR = 294 0.86, 95% CI = 0.80 to 9.13) (Supplementary File 1j, Figure 4-figure supplements 1-3). These 295 estimates were overlapping with variable precision in MR sensitivity models. When SNPs in the 296 FADS gene region were excluded, there was little evidence for a causal effect of any metabolite 297 investigated on CRC risk based on the predetermined FDR-P cut of off < 0.05, although the 298 directions of effect estimates were consistent with previous analyses (Supplementary File 1k). 299

In anatomical subtype stratified analyses evidence was strongest for an effect of fatty acid traits
 on higher CRC risk, and this appeared specific to the distal colon, e.g., omega-3 (distal CRC OR
 = 1.20, 95% CI = 1.09 to 1.32), and ratio of DHA to total fatty acids (distal colon OR = 1.29, 95%)

CI = 1.16 to 1.43). There was also evidence of a negative effect of ratio of omega-6 to omega-3 fatty acids (distal CRC OR = 0.80, 95% CI = 0.74 to 0.88) and a positive effect of ratio of omega-3 fatty acids to total fatty acids (distal CRC = 1.24, 95% CI = 1.15 to 1.35; seen also for proximal CRC OR = 1.15, 95% CI = 1.07 to 1.23) (**Supplementary File 1j**). These estimates were also directionally consistent in MR sensitivity models.

308

309

310 **Discussion**

311

312 Here, we used a reverse MR framework to identify circulating metabolites which are associated 313 with genetic CRC liability across different stages of the early life course and attempted to replicate 314 results in an independent cohort of middle-aged adults. We then performed forward MR to 315 characterise the causal direction of the relationship between metabolites and CRC. Our GRS 316 analysis provided evidence for an association of genetic liability to CRC with higher circulating 317 levels of lipoprotein lipids (including total cholesterol, VLDL-cholesterol, and LDL-cholesterol), 318 apolipoproteins (including apolipoprotein B), and fatty acids (including omega-3 and DHA) in 319 young adults. These results were largely consistent in direction (though smaller in magnitude and 320 weaker in strength of evidence) in a two-sample MR analysis in an independent cohort of middle-321 aged adults. Results were attenuated, but consistent in direction, when potentially pleiotropic 322 SNPs in the FADS gene regions were excluded. However, it should be noted that use of a narrow 323 window for exclusion based on being within one of the three FADS genes may mean that some 324 pleiotropic SNPs remain. Our subsequent forward MR analysis highlighted polyunsaturated fatty 325 acids as potentially having a causal role in the development of CRC.

326

327 Our analyses highlight a potentially important role of polyunsaturated fatty acids in colorectal 328 cancer liability. However, these analyses may be biased by substantial genetic pleiotropy among 329 fatty acid traits. SNPs which are associated with levels of one fatty acid are generally associated with levels of many more fatty acid (and non-fatty acid) traits.^{70,71} For instance, genetic instruments 330 331 within the FADS cluster of genes will likely affect both omega-3 and omega-6 fatty acids, given 332 FADS1 and FADS2 encode enzymes which catalyse the conversion of both from shorter chain into longer chain fatty acids.⁷¹ In addition, the NMR metabolomics platform utilised in the analyses 333 334 outlined here has limited coverage of fatty acids, meaning many putative causal metabolites for 335 CRC, for example arachidonic acid, could not be investigated. Therefore, although our results 336 indicate that polyunsaturated fatty acids may be important in colorectal cancer risk, given the

pleiotropic nature of the fatty acid genetic instruments and the limited coverage of the NMR
 platform, we are unable to determine with any certainty which specific classes of fatty acids may
 be driving these associations.

340

341 Our analyses featured evaluating the effect of genetic liability to CRC on circulating metabolites 342 across repeated measures in the ALSPAC cohort. The mean ages at the time of the repeated 343 measures were 8y, 16y, 18y, and 25y, representing childhood, early adolescence, late 344 adolescence, and young adulthood respectively, and therefore individuals in this cohort are 345 unlikely to be taking metabolite-altering medication such as statins, and unlikely to have CRC. 346 The strongest evidence for an effect of liability to CRC on metabolite levels was seen in late 347 adolescence. The reason for this remains unclear. It is possible that this represents a true 348 biological phenomenon if late adolescence is a critical window in CRC development or metabolite 349 variability, which may be likely given the limited variance in metabolite levels at the later age of 350 25y (**Supplementary File 1b**). The lack of an effect at the younger ages could be explained by 351 the fact that the CRC GRS may capture many key life events or experiences which could impact 352 the metabolome (e.g., initiation of smoking, higher category of BMI reached, educational 353 attainment level set, etc) but may not have yet happened at younger ages, thus obscuring an 354 effect of genetic liability to CRC on the metabolome. Our results suggest that puberty could be 355 important, with an effect seen seemingly particularly at the end of puberty. Repeating our analysis 356 with sex-stratified data may aid in determining whether this is likely to be the case; sex-stratified 357 GWAS for metabolites are not currently available to replicate such analyses. An alternative 358 explanation is selection bias due to loss of follow-up, leading to a change in sample characteristics 359 over time.

360

361 Another key finding in the reverse MR analysis was that genetic liability to CRC was associated 362 with increased levels of total cholesterol, VLDL-cholesterol, LDL-cholesterol, and apolipoprotein 363 B, though we find little evidence for a causal effect of these traits on risk of CRC in the forward 364 MR, replicating previous forward MR analyses for total and LDL-cholesterol.^{9,72–74} This suggests 365 that these traits may either be only predictive of (i.e., non-causal for) later CRC development, or 366 may be influenced by the development of CRC and could have diagnostic or predictive potential. 367 Given that the participants in the ALSPAC cohort are many decades younger than the average 368 age of diagnosis for CRC (mean age 25 years in the latest repeated measure analysed in 369 ALSPAC; whereas the median age at diagnosis of CRC is 64 years),⁷⁵ the former seems the most 370 likely scenario. Previous conventional observational studies have presented conflicting results

371 when investigating the association between measures of cholesterol and CRC risk with some 372 finding an inverse association and others a positive association, possibly reflecting residual 373 confounding in conventional observational analyses.^{76–82} Previous MR studies have had similar 374 findings to our forward MR analysis, in that there seems to be little evidence for a causal effect of 375 cholesterol on CRC development.^{72–74} One possible explanation for how circulating levels of total 376 cholesterol, VLDL-cholesterol, LDL-cholesterol and apolipoprotein B could predict (without 377 necessarily causing) future CRC development could be linked to diet. A previous MR analysis 378 suggested an effect of increased BMI on several measures of circulating cholesterol.⁹ Consuming 379 a diet which is high in fat may increase CRC risk both through and possibly independently of 380 adiposity, alongside increasing levels of circulating cholesterol.^{83–88} The potential for lipoprotein or apolipoprotein lipid measures in future CRC risk prediction should be further investigated. 381

382

Our analyses stratified by anatomical subsite highlighted fatty acids as being affected by genetic liability to colon and proximal colon cancer, with the forward MR confirming that fatty acid traits may be particularly important in the development of these subsites of CRC as well as distal colon cancer.

387

388 In our forward MR analyses we were unable to replicate the findings of three previous MR studies 389 which found evidence for a causal effect of circulating linoleic acid levels on CRC development in 390 terms of strength of evidence, though the direction of the effect estimate was similar to previous 391 studies.^{89–91} This is surprising as all three previous analyses had a much smaller sample size than 392 that included in our analysis (the largest had sample size of 24,748 for exposure vs 118,466 393 presently; and 11,016 cases and 13,732 controls for outcome vs 52,775 cases and 45,940 394 controls presently). Our analysis using updated genetic instruments to proxy fatty acids may be 395 more successful in accurately instrumenting heterogenous phenotypes such as metabolite levels 396 compared with previous analyses. All other findings in our forward MR analysis are consistent 397 with previous MR studies where they exist.^{72–74}

398

399 Limitations

400

The limitations of this study include firstly the relatively small sample size included in the ALSPAC analysis, which may have implications for power and precision. Secondly, mostly due to the longitudinal nature of the ASLAPC study, our sample at each time point is composed of slightly different individuals. This could be influencing our results, and should be taken into account when

405 comparing across time points. Thirdly, our analyses involving genetic instruments for CRC liability 406 may have suffered from horizontal pleiotropy, even after excluding genetic variants in or near the 407 FADS gene. Fourthly, our analyses were mostly restricted to white Europeans, which limits the 408 generalisability of our findings to other populations. Fifthly, our analysis would benefit from being 409 repeated with sex-stratified data. Although such GWAS results for metabolites are not currently 410 available, the data to perform such GWAS are available in UK Biobank for future analyses. Sixthly, 411 for our forward MR analysis, we used the UK Biobank for our exposure data. The UK Biobank 412 has a median age of 58 at the time these measurements were taken, meaning statin use may be 413 widespread in this population, which could be attenuating our effect estimates. Future work could 414 attempt to replicate our analysis in a population with lower prevalence of statins intake. Finally, 415 we included only metabolites measured using NMR. Confirming whether our results replicate 416 using metabolite data measured with an alternative method would strengthen our findings.

417

418 Conclusions

419

420 Our analysis provides evidence that genetic liability to CRC is associated with altered levels of

421 metabolites at certain ages, some of which may have a causal role in CRC development. Further

422 investigating the role of polyunsaturated fatty acids in CRC risk and circulating cholesterol in CRC

423 prediction may be promising avenues for future research.

424

425 Figure legends

426 Figure 1: Study design. First, linear regression models were used to examine the relationship 427 between genetic susceptibility to adult colorectal cancer and circulating metabolites measured in 428 ALSPAC participants at age 8, 16, 18 and 25 years. Next, we performed a reverse Mendelian 429 randomization analysis to identify metabolites influenced by CRC susceptibility in an 430 independent population of adults. Finally, we performed a conventional (forward) Mendelian 431 randomization analysis of circulating metabolites on CRC to identify metabolites causally 432 associated with CRC risk. Consistent evidence across all three methodological approaches was 433 interpreted to indicate a causal role for a given metabolite in CRC aetiology. 434

Figure 2: Associations of genetic liability to adult colorectal cancer (based on a 72 SNP genetic risk score) with clinically validated metabolic traits at different early life stages among ALSPAC offspring (age 8y (N=4,767), 16y (N=2,930), 18y (N=2,613), and 25y (N=2,559)). Estimates shown are beta coefficients representing the SD difference in metabolic trait per doubling of genetic liability to colorectal cancer (purple, 8y; turquoise, 16y; red, 18y; black, 25y). Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR < 0.05).

Figure 2-figure supplement 1: Associations of genetic liability to adult colon cancer with clinically validated metabolic traits at different early life stages among ALSPAC offspring (age 8y, 16y, 18y, and 25y). Estimates shown are beta coefficients representing the SD difference in
metabolic trait per doubling of genetic liability to colon cancer (purple, 8y; turquoise, 16y; red,
18y; black, 25y). Filled point estimates are those that pass a Benjamini–Hochberg FDR multipletesting correction (FDR < 0.05).

449

Figure 2-figure supplement 2: Associations of genetic liability to proximal colon cancer with
clinically validated metabolic traits at different early life stages among ALSPAC offspring (age
8y, 16y, 18y, and 25y). Estimates shown are beta coefficients representing the SD difference in
metabolic trait per doubling of genetic liability to proximal colon cancer (purple, 8y; turquoise,
16y; red, 18y; black, 25y). Filled point estimates are those that pass a Benjamini–Hochberg
FDR multiple-testing correction (FDR < 0.05).

456

Figure 2-figure supplement 3: Associations of genetic liability to distal colon cancer with
clinically validated metabolic traits at different early life stages among ALSPAC offspring (age
8y, 16y, 18y, and 25y). Estimates shown are beta coefficients representing the SD difference in
metabolic trait per doubling of genetic liability to distal colon cancer (purple, 8y; turquoise, 16y;
red, 18y; black, 25y). Filled point estimates are those that pass a Benjamini–Hochberg FDR
multiple-testing correction (FDR < 0.05).

Figure 2-figure supplement 4: Associations of genetic liability to rectal cancer with clinically
validated metabolic traits at different early life stages among ALSPAC offspring (age 8y, 16y,
18y, and 25y). Estimates shown are beta coefficients representing the SD difference in
metabolic trait per doubling of genetic liability to rectal cancer (purple, 8y; turquoise, 16y; red,
18y; black, 25y). Filled point estimates are those that pass a Benjamini–Hochberg FDR multipletesting correction (FDR < 0.05).

470

Figure 2-figure supplement 5: Associations of genetic liability to adult colorectal cancer
(excluding rs174533) with clinically validated metabolic traits at different early life stages among
ALSPAC offspring (age 8y, 16y, 18y, and 25y). Estimates shown are beta coefficients
representing the SD difference in metabolic trait per doubling of genetic liability to colorectal
cancer (purple, 8y; turquoise, 16y; red, 18y; black, 25y). Filled point estimates are those that
pass a Benjamini–Hochberg FDR multiple-testing correction (FDR < 0.05).

477

Figure 2-figure supplement 6: Associations of genetic liability to adult colon cancer (excluding
rs174535) with clinically validated metabolic traits at different early life stages among ALSPAC
offspring (age 8y, 16y, 18y, and 25y). Estimates shown are beta coefficients representing the
SD difference in metabolic trait per doubling of genetic liability to colorectal cancer cancer
(purple, 8y; turquoise, 16y; red, 18y; black, 25y). Filled point estimates are those that pass a
Benjamini–Hochberg FDR multiple-testing correction (FDR < 0.05).

484

Figure 3: Associations of genetic liability to colorectal cancer with clinically validated metabolic
traits in an independent sample of adults (UK Biobank, N=118,466, median age 58y) based on
reverse two sample Mendelian randomization analyses. Estimates shown are beta coefficients
representing the SD-unit difference in metabolic trait per doubling of liability to colorectal cancer.
Filled point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing
correction (FDR < 0.05).

- 492 **Figure 3-figure supplement 1:** Associations of genetic liability to colorectal cancer with
 - 493 clinically validated metabolic traits in an independent sample of adults based on reverse two
 494 sample Mendelian randomization analyses. Estimates shown are beta coefficients representing
 495 the SD-unit difference in metabolic trait per doubling of liability to colorectal cancer by site

496 (colorectal, colon, distal colon, proximal colon and rectal cancer). Filled point estimates are 497 those that pass a Benjamini–Hochberg FDR multiple-testing correction (FDR < 0.05).

498

499 Figure 3-figure supplement 2: Associations of genetic liability to colorectal cancer (excluding 500 genetic variants in the FADS gene region) with clinically validated metabolic traits in an 501 independent sample of adults based on reverse two sample Mendelian randomization analyses. 502 Estimates shown are beta coefficients representing the SD-unit difference in metabolic trait per 503 doubling of liability to colorectal cancer. Filled point estimates are those that pass a Benjamini-504 Hochberg FDR multiple-testing correction (FDR < 0.05). 505 506 Figure 3-figure supplement 3: Associations of genetic liability to colorectal and colon cancer 507 with clinically validated metabolic traits in an independent sample of adults based on reverse 508 two sample Mendelian randomization analyses with FADS variants excluded from colorectal 509 cancer instruments. Estimates shown are beta coefficients representing the SD-unit difference 510 in metabolic trait per doubling of liability to colorectal cancer by site (colorectal, colon). Filled 511 point estimates are those that pass a Benjamini–Hochberg FDR multiple-testing correction 512 (FDR < 0.05). 513 514 Figure 4: Associations of clinically validated metabolites with colorectal cancer based on 515 conventional (forward) two sample Mendelian randomization analyses in individuals from UK 516 Biobank (N=118,466, median age 58y). Estimates shown are beta coefficients representing the logOR for colorectal cancer per SD metabolite. Filled point estimates are those that pass a 517 518 Benjamini–Hochberg FDR multiple-testing correction (FDR < 0.05). 519 520 Figure 4-figure supplement 1: Associations of clinically validated metabolites with colorectal 521 cancer by site (colorectal, colon, distal colon, proximal colon and rectal cancer) based on 522 conventional (forward) two sample Mendelian randomization analyses. Estimates shown are 523 ORs for colorectal cancer per SD metabolite. Filled point estimates are those that pass a 524 Benjamini–Hochberg FDR multiple-testing correction (FDR < 0.05). 525 526 Supplementary file legends 527 Supplementary File 1a: Genetic variants used to construct genetic risk scores reflecting 528 colorectal cancer liability 529

- Supplementary File 1b: Mean and SD values for raw metabolic traits at different life stages
 among ALSPAC offspring
- 533 **Supplementary File 1c:** Associations of genetic liability to colorectal cancer with metabolic 534 traits at different early life stages among ALSPAC offspring
- 535
- Supplementary File 1d: Associations of genetic liability to colorectal cancer (excluding SNPs in
 the FADS gene region) with metabolic traits at different early life stages among ALSPAC
 offspring
- 539
- 540 **Supplementary File 1e:** Assessment of instrument strength for MR analyses 541

542 **Supplementary File 1f:** Associations of genetic liability to colorectal cancer with metabolic traits

- 543 based on two-sample MR
- 544

- **Supplementary File 1g:** Associations of genetic liability to colorectal cancer with metabolic 546 traits based on two-sample MR, excluding variants in the FADS gene region
- **Supplementary File 1h:** Genetic variants used to instrument circulating metabolites
- **Supplementary File 1i:** Assessment of instrument strength for MR analyses
- 551
 552 Supplementary File 1j: Estimated effects of circulating metabolites on colorectal cancer risk
 553 based on two-sample MR
- **Supplementary File 1k:** Estimated effects of circulating metabolites on colorectal cancer risk
- based on two-sample MR, excluding variants in the FADS gene region

557 References

- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* [Internet].
 Wiley-Liss Inc.; 2015 Mar 1 [cited 2022 Nov 17];**136**(5):E359–E386. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.29210
- 562 2. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update
 563 Project Expert Report. Diet, nutrition, physical activity and colorectal cancer. 2018;
- Huyghe JR, Bien SA, Harrison TA, et al. Discovery of common and rare genetic risk
 variants for colorectal cancer. *Nature Genetics 2018 51:1* [Internet]. Nature Publishing
 Group; 2018 Dec 3 [cited 2023 Mar 9];51(1):76–87. Available from: https://www.nature.com/articles/s41588-018-0286-6
- 568 4. Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer
 569 among 9.6 million individuals in the Swedish family-cancer database. *Int J Cancer*570 [Internet]. John Wiley & Sons, Ltd; 2002 May 10 [cited 2023 Mar 9];99(2):260–266.
 571 Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.10332
- Aul P, Ichtenstein L, Olm IVH, et al. Environmental and Heritable Factors in the
 Causation of Cancer Analyses of Cohorts of Twins from Sweden, Denmark, and
 Finland. *https://doi.org/101056/NEJM200007133430201* [Internet]. Massachusetts
 Medical Society ; 2000 Jul 13 [cited 2023 Mar 9];**343**(2):78–85. Available from:
- https://www.nejm.org/doi/full/10.1056/NEJM200007133430201
 Händel MN, Rohde JF, Jacobsen R, et al. Processed meat intake and incidence of colorectal cancer: a systematic review and meta-analysis of prospective observational studies. *European Journal of Clinical Nutrition 2020 74:8* [Internet]. Nature Publishing Group; 2020 Feb 6 [cited 2022 Nov 17];**74**(8):1132–1148. Available from: https://www.nature.com/articles/s41430-020-0576-9
- 582 7. McNabb S, Harrison TA, Albanes D, et al. Meta-analysis of 16 studies of the association
 583 of alcohol with colorectal cancer. *Int J Cancer* [Internet]. John Wiley & Sons, Ltd; 2020
 584 Feb 1 [cited 2022 Nov 17];**146**(3):861–873. Available from:
- 585 https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.32377
- Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body
 Fatness and Cancer--Viewpoint of the IARC Working Group. *N Engl J Med* [Internet]. N
 Engl J Med; 2016 Aug 25 [cited 2022 Nov 17];375(8):794–798. Available from:
 https://pubmed.ncbi.nlm.nih.gov/27557308/
- 590 9. Bull CJ, Bell JA, Murphy N, et al. Adiposity, metabolites, and colorectal cancer risk:
 591 Mendelian randomization study. *BMC Med* [Internet]. BioMed Central Ltd; 2020 Dec 1
 592 [cited 2023 Jan 10];18(1):1–16. Available from:
- 593 https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01855-9
- Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for Colorectal Cancer
 Screening. *Gastroenterology*. W.B. Saunders; 2020 Jan 1;158(2):418–432.
- 596 11. Cardoso R, Guo F, Heisser T, et al. Colorectal cancer incidence, mortality, and stage
 597 distribution in European countries in the colorectal cancer screening era: an international
 598 population-based study. *Lancet Oncol.* Elsevier; 2021 Jul 1;22(7):1002–1013.
- Qiu Y, Cai G, Su M, et al. Serum Metabolite Profiling of Human Colorectal Cancer Using
 GC-TOFMS and UPLC-QTOFMS. *J Proteome Res* [Internet]. American Chemical
 Society 2000 [cited 2022 New 17]: 9(10):4844, 4850. Available from:
- 601 Society; 2009 [cited 2022 Nov 17];**8**(10):4844–4850. Available from:
- 602 https://pubs.acs.org/doi/full/10.1021/pr9004162

603	13.	Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did
604	15.	not anticipate. <i>Cancer Cell</i> [Internet]. Cancer Cell; 2012 Mar 20 [cited 2022 Nov
605		17]; 21 (3):297–308. Available from: https://pubmed.ncbi.nlm.nih.gov/22439925/
606	14.	Rattray NJW, Charkoftaki G, Rattray Z, Hansen JE, Vasiliou V, Johnson CH.
607	14.	Environmental Influences in the Etiology of Colorectal Cancer: the Premise of
608		Metabolomics. <i>Current Pharmacology Reports 2017 3:3</i> [Internet]. Springer; 2017 Apr 7
608 609		
		[cited 2022 Nov 22]; 3 (3):114–125. Available from:
610	15	https://link.springer.com/article/10.1007/s40495-017-0088-z
611	15.	Singla P, Bardoloi A, Parkash AA. Metabolic effects of obesity: A review. <i>World J</i>
612		Diabetes [Internet]. Baishideng Publishing Group Inc; 2010 Jul 7 [cited 2022 Nov
613	16	17]; 1 (3):76. Available from: /pmc/articles/PMC3083889/
614	16.	Papandreou C, García-Gavilán J, Camacho-Barcia L, et al. Circulating Metabolites
615		Associated with Body Fat and Lean Mass in Adults with Overweight/Obesity. <i>Metabolites</i>
616		2021, Vol 11, Page 317 [Internet]. Multidisciplinary Digital Publishing Institute; 2021
617		May 13 [cited 2022 Nov 17]; 11 (5):317. Available from: https://www.mdpi.com/2218-
618	. –	1989/11/5/317/htm
619	17.	Ahmad S, Hammar U, Kennedy B, et al. Effect of General Adiposity and Central Body
620		Fat Distribution on the Circulating Metabolome: A Multicohort Nontargeted
621		Metabolomics Observational and Mendelian Randomization Study. <i>Diabetes</i> [Internet].
622		American Diabetes Association; 2022 Feb 1 [cited 2022 Nov 17]; 71 (2):329–339.
623		Available from: https://diabetesjournals.org/diabetes/article/71/2/329/138937/Effect-of-
624		General-Adiposity-and-Central-Body-Fat
625	18.	Haycock PC, Carolina Borges M, Burrows K, et al. The association between genetically
626		elevated polyunsaturated fatty acids and risk of cancer. www.thelancet.com [Internet].
627		2023 [cited 2023 Jul 31]; 91 . Available from:
628		http://practical.icr.ac.uk/.ajhttps://epi.grants.cancer.gov/interlymph/.akhttps://dceg.cancer.
629		gov/research/cancer-types/pancreas/panscan.
630	19.	Yarmolinsky J, Wade KH, Richmond RC, et al. Causal Inference in Cancer
631		Epidemiology: What Is the Role of Mendelian Randomization? [cited 2022 Nov 17];
632	• •	Available from: http://aacrjournals.org/cebp/article-pdf/27/9/995/2285730/995.pdf
633	20.	GD S, S E. 'Mendelian randomization': can genetic epidemiology contribute to
634		understanding environmental determinants of disease? Int J Epidemiol [Internet]. Int J
635		Epidemiol; 2003 [cited 2022 Nov 17]; 32 (1). Available from:
636		https://pubmed.ncbi.nlm.nih.gov/12689998/
637	21.	Holmes M v., Smith GD. Can Mendelian Randomization Shift into Reverse Gear? Clin
638		<i>Chem</i> [Internet]. Oxford Academic; 2019 Mar 1 [cited 2022 Nov 17];65(3):363–366.
639		Available from: https://academic.oup.com/clinchem/article/65/3/363/5608004
640	22.	Gao R, Wu C, Zhu Y, et al. Integrated Analysis of Colorectal Cancer Reveals Cross-
641		Cohort Gut Microbial Signatures and Associated Serum Metabolites. Gastroenterology.
642		W.B. Saunders; 2022 Oct 1; 163 (4):1024-1037.e9.
643	23.	Rattner JI, Kopciuk KA, Vogel HJ, et al. Early detection of treatment futility in patients
644		with metastatic colorectal cancer. Oncotarget [Internet]. Impact Journals, LLC; 2022
645		[cited 2022 Nov 22];13:61. Available from: /pmc/articles/PMC8746015/
646	24.	Leichtle AB, Nuoffer JM, Ceglarek U, et al. Serum amino acid profiles and their
647		alterations in colorectal cancer. Metabolomics [Internet]. Springer; 2012 Aug 16 [cited

2022 Nov 22];8(4):643–653. Available from: 649 https://link.springer.com/article/10.1007/s11306-011-0357-5 650 Ritchie SA, Ahiahonu PWK, Jayasinghe D, et al. Reduced levels of hydroxylated, 25. 651 polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: Implications for early screening and detection. BMC Med [Internet]. BioMed Central; 652 653 2010 Feb 15 [cited 2022 Nov 22];8(1):1–20. Available from: 654 https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-8-13 655 26. Nishiumi S, Kobayashi T, Ikeda A, et al. A Novel Serum Metabolomics-Based Diagnostic 656 Approach for Colorectal Cancer. PLoS One [Internet]. Public Library of Science; 2012 Jul 11 [cited 2022 Nov 22];7(7):e40459. Available from: 657 658 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040459 659 27. Ma Y, Zhang P, Wang F, Liu W, Yang J, Qin H. An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. Ann 660 Surg [Internet]. 2012 Apr [cited 2022 Nov 22];255(4):720–730. Available from: 661 662 https://journals.lww.com/annalsofsurgery/Fulltext/2012/04000/An Integrated Proteomics 663 and Metabolomics Approach.17.aspx 664 28. Bertini I, Cacciatore S, Jensen B v., et al. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res [Internet]. 665 American Association for Cancer Research; 2012 Jan 1 [cited 2022 Nov 22];72(1):356-666 667 364. Available from: 668 https://aacrjournals.org/cancerres/article/72/1/356/575915/Metabolomic-NMR-669 Fingerprinting-to-Identify-and 670 Zhang A, Sun H, Yan G, Wang P, Han Y, Wang X. Metabolomics in diagnosis and 29. 671 biomarker discovery of colorectal cancer. Cancer Lett. Elsevier; 2014 Apr 1:345(1):17-672 20. 673 30. Farshidfar F, Weljie AM, Kopciuk KA, et al. A validated metabolomic signature for 674 colorectal cancer: exploration of the clinical value of metabolomics. British Journal of 675 Cancer 2016 115:7 [Internet]. Nature Publishing Group; 2016 Aug 25 [cited 2022 Nov 676 22];115(7):848–857. Available from: https://www.nature.com/articles/bjc2016243 677 Farshidfar F. Welije AM, Kopciuk K, et al. Serum metabolomic profile as a means to 31. 678 distinguish stage of colorectal cancer. Genome Med [Internet]. BioMed Central; 2012 May 679 14 [cited 2022 Nov 22];**4**(5):1–13. Available from: 680 https://genomemedicine.biomedcentral.com/articles/10.1186/gm341 Boyd A, Golding J, Macleod J, et al. Cohort Profile: The 'Children of the 90s'—the index 681 32. 682 offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol. 2013 683 Feb;**42**(1):111–127. 684 33. Fraser A, Macdonald-Wallis C, Tilling K, et al. Cohort Profile: The Avon Longitudinal 685 Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol. 2013 Feb 686 1;42(1):97–110. 687 34. Northstone K, Lewcock M, Groom A, et al. The Avon Longitudinal Study of Parents and 688 Children (ALSPAC): an update on the enrolled sample of index children in 2019. 689 Wellcome Open Res [Internet]. The Wellcome Trust; 2019 [cited 2023 Feb 28];4. 690 Available from: /pmc/articles/PMC6464058/ 691 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic 35. 692 Data Capture (REDCap) - A metadata-driven methodology and workflow process for 693 providing translational research informatics support. J Biomed Inform [Internet]. NIH

648

694 Public Access; 2009 Apr [cited 2023 Feb 28];42(2):377. Available from: 695 /pmc/articles/PMC2700030/ 696 Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for 36. 697 Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. 698 PLoS Med [Internet]. Public Library of Science; 2015 Mar 1 [cited 2022 Nov 699 22];**12**(3):e1001779. Available from: 700 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001779 701 37. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping 702 and genomic data. *Nature 2018 562:7726* [Internet]. Nature Publishing Group; 2018 Oct 703 10 [cited 2022 Nov 22];562(7726):203-209. Available from: 704 https://www.nature.com/articles/s41586-018-0579-z 705 38. Huyghe JR, Bien SA, Harrison TA, et al. Discovery of common and rare genetic risk 706 variants for colorectal cancer. Nat Genet. 2019;51(1):76-87. 707 39. Huyghe JR, Harrison TA, Bien SA, et al. Genetic architectures of proximal and distal 708 colorectal cancer are partly distinct. Gut [Internet]. Gut; 2021 Jul 1 [cited 2023 Jan 709 27];**70**(7):1325–1334. Available from: https://pubmed.ncbi.nlm.nih.gov/33632709/ 710 40. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample 711 Mendelian randomization. Genet Epidemiol. 2016;40(7):597-608. 712 Law PJ, Timofeeva M, Fernandez-Rozadilla C. Association analyses identify 31 new risk 41. 713 loci for colorectal cancer susceptibility. 714 42. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal 715 inference across the human phenome. *Elife*. 2018 May 30:7. 716 Huyghe JR, Harrison TA, Bien SA, et al. Genetic architectures of proximal and distal 43. 717 colorectal cancer are partly distinct. Gut. Gut; 2021 Jul 1;70(7):1325–1334. Lu T, Sun L, Wang Z, Zhang Y, He Z, Xu C. Fatty acid synthase enhances colorectal 718 44. 719 cancer cell proliferation and metastasis via regulating AMPK/mTOR pathway. Onco 720 Targets Ther [Internet]. Dove Press; 2019 [cited 2022 Nov 22];12:3339. Available from: 721 /pmc/articles/PMC6504633/ 722 45. Zaytseva YY, Rychahou PG, Le AT, et al. Preclinical evaluation of novel fatty acid 723 synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft 724 model of colorectal cancer. Oncotarget [Internet]. Impact Journals, LLC; 2018 May 5 725 [cited 2022 Nov 22];9(37):24787. Available from: /pmc/articles/PMC5973868/ 726 46. TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial. - Full 727 Text View - ClinicalTrials.gov [Internet]. [cited 2022 Nov 22]. Available from: 728 https://clinicaltrials.gov/ct2/show/NCT02980029 729 47. Fhu CW, Ali A. Fatty Acid Synthase: An Emerging Target in Cancer. Molecules 730 [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2020 Sep 1 [cited 2022] 731 Nov 22];25(17). Available from: /pmc/articles/PMC7504791/ 732 48. Chen HY, Cairns BJ, Small AM, et al. Association of FADS1/2 Locus Variants and 733 Polyunsaturated Fatty Acids With Aortic Stenosis. JAMA Cardiol [Internet]. American 734 Medical Association; 2020 Jun 1 [cited 2022 Nov 22];5(6):694–702. Available from: 735 https://jamanetwork.com/journals/jamacardiology/fullarticle/2762845 736 49. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nature Genetics 2008 41:1 [Internet]. Nature Publishing Group; 737 738 2008 Dec 7 [cited 2022 Nov 22];**41**(1):56–65. Available from: 739 https://www.nature.com/articles/ng.291

740 50. Tanaka T, Shen J, Abecasis GR, et al. Genome-Wide Association Study of Plasma 741 Polyunsaturated Fatty Acids in the InCHIANTI Study. PLoS Genet [Internet]. Public 742 Library of Science; 2009 Jan [cited 2022 Nov 22];5(1):e1000338. Available from: 743 https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1000338 744 Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. 51. 745 Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale 746 Epidemiology: A Primer on -Omic Technologies. Am J Epidemiol. Oxford Academic; 747 2017 Nov 1;186(9):1084-1096. 748 52. Julkunen H, Cichońska A, Slagboom PE, Würtz P. Metabolic biomarker profiling for 749 identification of susceptibility to severe pneumonia and COVID-19 in the general 750 population. *Elife*. eLife Sciences Publications Ltd; 2021 May 1;10. 751 53. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping 752 and genomic data. Nature 2018 562:7726. Nature Publishing Group; 2018 Oct 753 10;562(7726):203-209. 754 54. Holmes M V., Smith GD. Can Mendelian randomization shift into reverse gear? Clin 755 Chem American Association for Clinical Chemistry Inc.; 2019. p. 363–366. 756 55. Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates. Eur J Epidemiol [Internet]. Eur J 757 758 Epidemiol; 2018 Oct 1 [cited 2023 Jan 9];33(10):947–952. Available from: 759 https://pubmed.ncbi.nlm.nih.gov/30039250/ 760 Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and 56. 761 Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B 762 (Methodological) [Internet]. John Wiley & Sons, Ltd; 1995 Jan 1 [cited 2022 Nov 763 22];**57**(1):289–300. Available from: 764 https://onlinelibrary.wiley.com/doi/full/10.1111/j.2517-6161.1995.tb02031.x 765 57. Clayton GL, Borges MC, Lawlor DA. From menarche to menopause: the impact of 766 reproductive factors on the metabolic profile of over 65,000 women. 2022 Apr 18 [cited 767 2023 Jan 27]; Available from: https://europepmc.org/article/PPR/PPR484113 768 58. Borges MC, Haycock PC, Zheng J, et al. Role of circulating polyunsaturated fatty acids on 769 cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid 770 genetic association data from over 114,000 UK Biobank participants. BMC Med 771 [Internet]. BMC Med; 2022 Dec 1 [cited 2023 Jan 27];**20**(1). Available from: 772 https://pubmed.ncbi.nlm.nih.gov/35692035/ 773 MRC IEU UK Biobank GWAS pipeline version 2 - Datasets - data.bris [Internet]. [cited 59. 774 2022 Oct 14]. Available from: 775 https://data.bris.ac.uk/data/dataset/pnoat8cxo0u52p6ynfaekeigi Elsworth B, Lyon M, Alexander T, et al. The MRC IEU OpenGWAS data infrastructure. 776 60. 777 Gibran Hemani Kaitlin H Wade, Charles Laurin, Benjamin Elsworth, Stephen Burgess, 61. 778 Jack Bowden, Ryan Langdon, Vanessa Tan, James Yarmolinsky, Hashem A. Shihab, 779 Nicholas Timpson, David M Evans, Caroline Relton, Richard M Martin, George Davey 780 Smith, Tom R G JZ. MR-Base: a platform for systematic causal inference across the 781 phenome using billions of genetic associations. Biorxiv; 2016. 782 62. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian 783 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. 784 Genet Epidemiol. 2016;40(4):304-314.

- 63. Hartwig FP, Smith GD, Bowden J. Robust inference in summary data Mendelian
 randomization via the zero modal pleiotropy assumption. *Int J Epidemiol*. Oxford
 Academic; 2017 Dec 1;46(6):1985–1998.
- Hartwig FP, Smith GD, Bowden J. Robust inference in summary data Mendelian
 randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* [Internet]. Int J
 Epidemiol; 2017 Dec 1 [cited 2023 Jan 9];46(6):1985–1998. Available from:
- 791 https://pubmed.ncbi.nlm.nih.gov/29040600/
- Hartwig FP, Smith GD, Bowden J. Robust inference in summary data Mendelian
 randomization via the zero modal pleiotropy assumption. [cited 2023 Aug 1]; Available
 from: https://academic.oup.com/ije/article/46/6/1985/3957932
- Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable:
 interpretation and presentation of causal estimates.
- 797 67. R Core Team. R: A language and environment for statistical computing. R Foundation for
 798 Statistical Computing, Vienna, Austria.; 2020.
- Forestplots of Measures of Effects and Their Confidence Intervals ggforestplot[Internet]. [cited 2022 Oct 14]. Available from:
- 801 https://nightingalehealth.github.io/ggforestplot/index.html
- Boyd A, Golding J, Macleod J, et al. Cohort Profile: The 'Children of the 90s'—the index offspring of the Avon Longitudinal Study of Parents and Children. *Int J Epidemiol*Internet]. Oxford Academic; 2013 Feb 1 [cited 2023 Jan 27];42(1):111–127. Available
- 805 from: https://academic.oup.com/ije/article/42/1/111/694290
- 806 70. Borges MC, Haycock PC, Zheng J, et al. Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid
 808 genetic association data from over 114,000 UK Biobank participants. *BMC Med*809 [Internet]. BioMed Central Ltd; 2022 Dec 1 [cited 2023 Jan 30];20(1):1–14. Available
- 810 from: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-022-02399-w
- 811 71. Borges MC, Haycock P, Zheng J, et al. The impact of fatty acids biosynthesis on the risk
 812 of cardiovascular diseases in Europeans and East Asians: a Mendelian randomization
 813 study. *Hum Mol Genet* [Internet]. Oxford Academic; 2022 Nov 28 [cited 2023 Feb
 814 28];**31**(23):4034–4054. Available from:
- 815 https://academic.oup.com/hmg/article/31/23/4034/6633188
- 816 72. Rodriguez-Broadbent H, Law PJ, Sud A, et al. Mendelian randomisation implicates
 817 hyperlipidaemia as a risk factor for colorectal cancer. *Int J Cancer* [Internet]. Int J Cancer;
- 818 2017 Jun 15 [cited 2022 Nov 28];**140**(12):2701–2708. Available from:
- 819 https://pubmed.ncbi.nlm.nih.gov/28340513/
- 73. Cornish AJ, Law PJ, Timofeeva M, et al. Modifiable pathways for colorectal cancer: a
 mendelian randomisation analysis. *Lancet Gastroenterol Hepatol* [Internet]. Lancet
 Gastroenterol Hepatol; 2020 Jan 1 [cited 2022 Nov 28];5(1):55–62. Available from:
 https://pubmed.ncbi.nlm.nih.gov/31668584/
- Kuo X, Tu Z, Chen H, Ding J. Blood lipids and risk of colon or rectal cancer: a Mendelian randomization study. *J Cancer Res Clin Oncol* [Internet]. J Cancer Res Clin Oncol; 2021
 Dec 1 [cited 2022 Nov 28];**147**(12):3591–3599. Available from:
- 827 https://pubmed.ncbi.nlm.nih.gov/34490583/
- 828 75. Granados-Romero JJ, Valderrama-Treviño A, Hazzel E, Flores C, Herrera M. Colorectal
 829 cancer: a review. *Article in International Journal of Research in Medical Sciences*

- 830 [Internet]. 2017 [cited 2022 Nov 17]; Available from: http://dx.doi.org/10.18203/2320 831 6012.ijrms20174914
- Park SK, Joo JS, Kim DH, Kim YE, Kang D, Yoo KY. Association of serum lipids and
 glucose with the risk of colorectal adenomatous polyp in men: a case-control study in
 Korea. *J Korean Med Sci* [Internet]. Korean Academy of Medical Science; 2000 Dec 1
 [cited 2022 Nov 17];15(6):690–695. Available from:
- 836 https://doi.org/10.3346/jkms.2000.15.6.690
- Yang Z, Tang H, Lu S, Sun X, Rao B. Relationship between serum lipid level and
 colorectal cancer: a systemic review and meta-analysis. *BMJ Open* [Internet]. British
 Medical Journal Publishing Group; 2022 Jun 1 [cited 2022 Nov 17];**12**(6):e052373.
 Available from: https://bmjopen.bmj.com/content/12/6/e052373
- Tian Y, Wang K, Li J, et al. The association between serum lipids and colorectal
 neoplasm: a systemic review and meta-analysis. *Public Health Nutr* [Internet]. Cambridge
 University Press; 2015 Mar 16 [cited 2022 Nov 17];18(18):3355–3370. Available from:
 https://www.cambridge.org/core/journals/public-health-nutrition/article/associationbetween-serum-lipids-and-colorectal-neoplasm-a-systemic-review-and-
- 846 metaanalysis/4401DD8E09A7A257C95F1F3189E3B845
- Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective
 studies. *Cancer Causes and Control* [Internet]. Kluwer Academic Publishers; 2015 Feb 1
 [cited 2022 Nov 17];26(2):257–268. Available from:
- 850 https://link.springer.com/article/10.1007/s10552-014-0507-y
- 80. Mayengbam SS, Singh A, Pillai AD, Bhat MK. Influence of cholesterol on cancer
 progression and therapy. *Transl Oncol*. Elsevier; 2021 Jun 1;**14**(6):101043.
- 81. Mannes GA, Maier A, Thieme C, Wiebecke B, Paumgartner G. Relation between the
 Frequency of Colorectal Adenoma and the Serum Cholesterol Level. *http://dx.doi.org/101056/NEJM198612253152602* [Internet]. Massachusetts Medical
 Society ; 2009 Nov 16 [cited 2022 Nov 17];**315**(26):1634–1638. Available from:
 https://www.nejm.org/doi/full/10.1056/NEJM198612253152602
- 858
 82. Mamtani R, Lewis JD, Scott FI, et al. Disentangling the Association between Statins,
 Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. *PLoS Med* [Internet].
 Public Library of Science; 2016 Apr 1 [cited 2022 Nov 17];13(4):e1002007. Available
 from: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002007
- 862 83. Ocvirk S, Wilson AS, Appolonia CN, Thomas TK, O'Keefe SJD. Fiber, Fat, and
 863 Colorectal Cancer: New Insight into Modifiable Dietary Risk Factors. *Curr Gastroenterol*864 *Rep* [Internet]. Springer; 2019 Nov 1 [cited 2022 Nov 17];**21**(11):1–7. Available from:
 865 https://link.springer.com/article/10.1007/s11894-019-0725-2
- 866 84. Tang FY, Pai MH, Chiang EPI. Consumption of high-fat diet induces tumor progression
 867 and epithelial-mesenchymal transition of colorectal cancer in a mouse xenograft model. J
 868 Nutr Biochem. Elsevier; 2012 Oct 1;23(10):1302–1313.
- 869 85. Bell AE, Culp PA. Reduction in Saturated Fat Intake for Cardiovascular Disease. *Am Fam*870 *Physician* [Internet]. NLM (Medline); 2022 Jan 1 [cited 2022 Nov 17];**105**(1). Available
 871 from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011737.pub2/full
- 872 86. Chiu S, Williams PT, Krauss RM. Effects of a very high saturated fat diet on LDL
- 873 particles in adults with atherogenic dyslipidemia: A randomized controlled trial. *PLoS* 874 One Unternetl, Public Library of Science: 2017 Eeb 1 [cited 2022 New
- 874 *One* [Internet]. Public Library of Science; 2017 Feb 1 [cited 2022 Nov

875 17];**12**(2):e0170664. Available from: 876 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0170664 877 Han Q, Yeung SC, Ip MSM, Mak JCW. Dysregulation of cardiac lipid parameters in high-87. 878 fat high-cholesterol diet-induced rat model. [cited 2022 Nov 17]; Available from: https://doi.org/10.1186/s12944-018-0905-3 879 880 Vincent MJ, Allen B, Palacios OM, Haber LT, Maki KC. Meta-regression analysis of the 88. 881 effects of dietary cholesterol intake on LDL and HDL cholesterol. Am J Clin Nutr 882 [Internet]. Oxford Academic; 2019 Jan 1 [cited 2022 Nov 17];**109**(1):7–16. Available 883 from: https://academic.oup.com/ajcn/article/109/1/7/5266898 884 May-Wilson S, Sud A, Law PJ, et al. Pro-inflammatory fatty acid profile and colorectal 89. 885 cancer risk: A Mendelian randomisation analysis. Eur J Cancer [Internet]. Eur J Cancer; 886 2017 Oct 1 [cited 2022 Nov 28];84:228–238. Available from: 887 https://pubmed.ncbi.nlm.nih.gov/28829991/ 888 90. Khankari NK, Banbury BL, Borges MC, et al. Mendelian Randomization of Circulating 889 Polyunsaturated Fatty Acids and Colorectal Cancer Risk. Cancer Epidemiol Biomarkers 890 Prev [Internet]. Cancer Epidemiol Biomarkers Prev; 2020 [cited 2022 Nov 23];29(4):860-891 870. Available from: https://pubmed.ncbi.nlm.nih.gov/32051193/ 892 Livanage UE, Ong JS, An J, Gharahkhani P, Law MH, MacGregor S. Mendelian 91. 893 Randomization Study for Genetically Predicted Polyunsaturated Fatty Acids Levels on 894 Overall Cancer Risk and Mortality. Cancer Epidemiol Biomarkers Prev [Internet]. Cancer 895 Epidemiol Biomarkers Prev; 2019 Jun 1 [cited 2022 Nov 23];28(6):1015–1023. Available 896 from: https://pubmed.ncbi.nlm.nih.gov/30948449/ 897 898 Acknowledgements: ALSPAC: We are extremely grateful to all the families who took part in this 899 study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes 900 interviewers, computer and laboratory technicians, clerical workers, research scientists, 901 volunteers, managers, receptionists and nurses. 902 EPICOLON: We are sincerely grateful to all patients participating in this study who were recruited 903 as part of the EPICOLON project. We acknowledge the Spanish National DNA Bank, Biobank of 904 Hospital Clínic–IDIBAPS and Biobanco Vasco for the availability of the samples. The work was 905 carried out (in part) at the Esther Koplowitz Centre, Barcelona. 906 907 908 Data availability: Individual-level ALSPAC data are available following an application. This 909 process of managed access is detailed at www.bristol.ac.uk/alspac/researchers/access. Cohort 910 details and data descriptions for ALSPAC are publicly available at the same web address. 911 Summary-level GWAS data used in this study from UK Biobank are publicly available without the 912 for application through the MR-Base platform, which is accessible need at 913 http://www.mrbase.org/. The summary-level GWAS data for CRC used in this study are available 914 following an application to GECCO (managed access). All data generated by this study are

- 915 available in the manuscript and supporting material. R scripts used in this study have been made
- 916 publicly available on GitHub at: https://github.com/cb12104/adiposity_metabolites_crc.
- 917

918 **Funding**:

919 Author funding

920 JAB is supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol 921 and the Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z) and works in a Unit 922 funded by the Medical Research Council (MC UU 00011/1) and the University of Bristol. EEV, 923 DNL and CB are supported by Diabetes UK (17/0005587). NJT is a Wellcome Trust Investigator 924 (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 925 102215/2/13/2), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-926 1215-20011), the MRC Integrative Epidemiology Unit (MC UU 00011/1) and works within the 927 CRUK Integrative Cancer Epidemiology Programme (C18281/A19169). EH is supported by a 928 Cancer Research UK Population Research Committee Studentship (C18281/A30905), is 929 supported by the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019) and is 930 part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol 931 which is supported by the Medical Research Council (MC UU 00011/4) and the University of 932 Bristol. AC acknowledges funding from grant MR/N0137941/1 for the GW4 BIOMED MRC DTP, 933 awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council 934 (MRC)/UKRI. MCB was supported by the UK Medical Research Council (MRC) Skills 935 Development Fellowship (MR/P014054/1), University of Bristol Vice-Chancellor's Fellowship and 936 MRC Integrative Epidemiology Unit (MC_UU_00011/6). The funders had no role in study design, 937 data collection and analysis, decision to publish, or preparation of the manuscript. This work used 938 the computational facilities of the Advanced Computing Research Centre, University of Bristol -939 http://www.bristol.ac.uk/acrc/.

940

941 Study funding

ALSPAC: The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors who will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grantacknowledgements.pdf); This research was specifically funded by The UK Medical Research Council (Grant ref: MC_UU_12013/1). GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation ofAmerica) using support from 23andMe.

950

Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO): National Cancer
Institute, National Institutes of Health, U.S. Department of Health and Human Services (U01
CA137088, R01 CA059045, R01 201407). Genotyping/Sequencing services were provided by
the Center for Inherited Disease Research (CIDR) contract number HHSN268201700006I and
HHSN268201200008I. This research was funded in part through the NIH/NCI Cancer Center
Support Grant P30 CA015704. Scientific Computing Infrastructure at Fred Hutch funded by
ORIP grant S100D028685.

- 958 ASTERISK: a Hospital Clinical Research Program (PHRC-BRD09/C) from the University
- 959 Hospital Center of Nantes (CHU de Nantes) and supported by the Regional Council of Pays de

960 la Loire, the Groupement des Entreprises Françaises dans la Lutte contre le Cancer (GEFLUC),

- the Association Anne de Bretagne Génétique and the Ligue Régionale Contre le Cancer
- 962 (LRCC).

The ATBC Study is supported by the Intramural Research Program of the U.S. National Cancer
Institute, National Institutes of Health, Department of Health and Human Services.

965 CLUE II funding was from the National Cancer Institute (U01 CA086308, Early Detection

966 Research Network; P30 CA006973), National Institute on Aging (U01 AG018033), and the

967 American Institute for Cancer Research. The content of this publication does not necessarily

reflect the views or policies of the Department of Health and Human Services, nor does mention

- 969 of trade names, commercial products, or organizations imply endorsement by the US
- 970 government.

971 Maryland Cancer Registry (MCR): Cancer data was provided by the Maryland Cancer Registry,

972 Center for Cancer Prevention and Control, Maryland Department of Health, with funding from

- 973 the State of Maryland and the Maryland Cigarette Restitution Fund. The collection and
- 974 availability of cancer registry data is also supported by the Cooperative Agreement
- 975 NU58DP006333, funded by the Centers for Disease Control and Prevention. Its contents are
- solely the responsibility of the authors and do not necessarily represent the official views of the
- 977 Centers for Disease Control and Prevention or the Department of Health and Human Services.

ColoCare: This work was supported by the National Institutes of Health (grant numbers R01
CA189184 (Li/Ulrich), U01 CA206110 (Ulrich/Li/Siegel/Figueiredo/Colditz, 2P30CA015704- 40
COLOCARE: This work was supported by the National Institutes of Health (grant numbers R01
CA189184 (Li/Ulrich), U01 CA206110 (Ulrich/Li/Siegel/Figueiredo/Colditz, 2P30CA015704- 40
COLOCARE: This work was supported by the National Institutes of Health (grant numbers R01
CA189184 (Li/Ulrich), U01 CA206110 (Ulrich/Li/Siegel/Figueiredo/Colditz, 2P30CA015704- 40
COLOCARE: This work was supported by the National Institutes of Health (grant numbers R01

980 (Gilliland), R01 CA207371 (Ulrich/Li)), the Matthias Lackas-Foundation, the German Consortium

981 for Translational Cancer Research, and the EU TRANSCAN initiative.

982 The Colon Cancer Family Registry (CCFR, www.coloncfr.org) is supported in part by funding 983 from the National Cancer Institute (NCI), National Institutes of Health (NIH) (award U01 984 CA167551). Support for case ascertainment was provided in part from the Surveillance, 985 Epidemiology, and End Results (SEER) Program and the following U.S. state cancer registries: 986 AZ, CO, MN, NC, NH; and by the Victoria Cancer Registry (Australia) and Ontario Cancer 987 Registry (Canada). The CCFR Set-1 (Illumina 1M/1M-Duo) and Set-2 (Illumina Omni1-Quad) 988 scans were supported by NIH awards U01 CA122839 and R01 CA143237 (to GC). The CCFR 989 Set-3 (Affymetrix Axiom CORECT Set array) was supported by NIH award U19 CA148107 and 990 R01 CA81488 (to SBG). The CCFR Set-4 (Illumina OncoArray 600K SNP array) was supported 991 by NIH award U19 CA148107 (to SBG) and by the Center for Inherited Disease Research 992 (CIDR), which is funded by the NIH to the Johns Hopkins University, contract number 993 HHSN268201200008I. Additional funding for the OFCCR/ARCTIC was through award GL201-994 043 from the Ontario Research Fund (to BWZ), award 112746 from the Canadian Institutes of 995 Health Research (to TJH), through a Cancer Risk Evaluation (CaRE) Program grant from the 996 Canadian Cancer Society (to SG), and through generous support from the Ontario Ministry of 997 Research and Innovation. The SFCCR Illumina HumanCytoSNP array was supported in part 998 through NCI/NIH awards U01/U24 CA074794 and R01 CA076366 (to PAN). The content of this 999 manuscript does not necessarily reflect the views or policies of the NCI, NIH or any of the 1000 collaborating centers in the Colon Cancer Family Registry (CCFR), nor does mention of trade 1001 names, commercial products, or organizations imply endorsement by the US Government, any 1002 cancer registry, or the CCFR.

1003 COLON: The COLON study is sponsored by Wereld Kanker Onderzoek Fonds, including funds 1004 from grant 2014/1179 as part of the World Cancer Research Fund International Regular Grant 1005 Programme, by Alpe d'Huzes and the Dutch Cancer Society (UM 2012–5653, UW 2013-5927, 1006 UW2015-7946), and by TRANSCAN (JTC2012-MetaboCCC, JTC2013-FOCUS). The Ngplus 1007 study is sponsored by a ZonMW investment grant (98-10030); by PREVIEW, the project 1008 PREVention of diabetes through lifestyle intervention and population studies in Europe and 1009 around the World (PREVIEW) project which received funding from the European Union Seventh 1010 Framework Programme (FP7/2007–2013) under grant no. 312057; by funds from TI Food and

- 1011 Nutrition (cardiovascular health theme), a public–private partnership on precompetitive research
- 1012 in food and nutrition; and by FOODBALL, the Food Biomarker Alliance, a project from JPI
- 1013 Healthy Diet for a Healthy Life.
- 1014 COLO2&3: National Institutes of Health (R01 CA060987)
- 1015 Colorectal Cancer Transdisciplinary (CORECT) Study: The CORECT Study was supported by
- 1016 the National Cancer Institute, National Institutes of Health (NCI/NIH), U.S. Department of Health
- and Human Services (grant numbers U19 CA148107, R01 CA081488, P30 CA014089, R01
- 1018 CA197350; P01 CA196569; R01 CA201407; R01 CA242218), National Institutes of
- 1019 Environmental Health Sciences, National Institutes of Health (grant number T32 ES013678) and
- 1020 a generous gift from Daniel and Maryann Fong.
- 1021 CORSA: The CORSA study was funded by Austrian Research Funding Agency (FFG) BRIDGE
- 1022 (grant 829675, to Andrea Gsur), the "Herzfelder'sche Familienstiftung" (grant to Andrea Gsur)1023 and was supported by COST Action BM1206.
- 1024 CPS-II: The American Cancer Society funds the creation, maintenance, and updating of the
 1025 Cancer Prevention Study-II (CPS-II) cohort. The study protocol was approved by the institutional
 1026 review boards of Emory University, and those of participating registries as required.
- 1027 CRCGEN: Colorectal Cancer Genetics & Genomics, Spanish study was supported by Instituto
- 1028 de Salud Carlos III, co-funded by FEDER funds –a way to build Europe– (grants PI14-613 and
- 1029 PI09-1286), Agency for Management of University and Research Grants (AGAUR) of the
- 1030 Catalan Government (grant 2017SGR723), Junta de Castilla y León (grant LE22A10-2), the
- 1031 Spanish Association Against Cancer (AECC) Scientific Foundation grant GCTRA18022MORE
- 1032 and the Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP),
- 1033 action Genrisk. Sample collection of this work was supported by the Xarxa de Bancs de Tumors
- 1034 de Catalunya sponsored by Pla Director d'Oncología de Catalunya (XBTC), Plataforma
- 1035 Biobancos PT13/0010/0013 and ICOBIOBANC, sponsored by the Catalan Institute of Oncology.
- 1036 We thank CERCA Programme, Generalitat de Catalunya for institutional support.
- 1037 Czech Republic CCS: This work was supported by the Grant Agency of the Czech Republic (21-
- 1038 04607X, 20-03997S), by the Grant Agency of the Ministry of Health of the Czech Republic
- 1039 (grants AZV NU21-07-00247 and AZV NU21-03-00506), and Charles University Research Fund
- 1040 (Cooperation 43-Surgical disciplines)

- 1041 DACHS: This work was supported by the German Research Council (BR 1704/6-1, BR 1704/6-
- 1042 3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1 and BR
- 1043 1704/17-1), the Interdisciplinary Research Program of the National Center for Tumor Diseases
- 1044 (NCT), Germany, and the German Federal Ministry of Education and Research (01KH0404,
- 1045 01ER0814, 01ER0815, 01ER1505A and 01ER1505B).
- 1046 DALS: National Institutes of Health (R01 CA048998 to M. L. Slattery).
- 1047 EDRN: This work is funded and supported by the NCI, EDRN Grant (U01-CA152753).


1048 EPIC: The coordination of EPIC is financially supported by International Agency for Research 1049 on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of 1050 Public Health, Imperial College London which has additional infrastructure support provided by 1051 the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: 1052 Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle 1053 Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale 1054 (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German 1055 Institute of Human Nutrition Potsdam- Rehbruecke (DIFE), Federal Ministry of Education and 1056 Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, 1057 Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, 1058 Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch 1059 Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund 1060 (WCRF). Statistics Netherlands (The Netherlands): Health Research Fund (FIS) - Instituto de 1061 Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia 1062 and Navarra, and the Catalan Institute of Oncology - ICO (Spain): Swedish Cancer Society, 1063 Swedish Research Council and and Region Skåne and Region Västerbotten (Sweden); Cancer 1064 Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research 1065 Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford). (United Kingdom).

EPICOLON: This work was supported by grants from Fondo de Investigación Sanitaria/FEDER
(PI08/0024, PI08/1276, PS09/02368, PI11/00219, PI11/00681, PI14/00173, PI14/00230,
PI17/00509, 17/00878, PI20/00113, PI20/00226, Acción Transversal de Cáncer), Xunta de
Galicia (PGIDIT07PXIB9101209PR), Ministerio de Economia y Competitividad (SAF07-64873,
SAF 2010-19273, SAF2014-54453R), Fundación Científica de la Asociación Española contra el
Cáncer (GCB13131592CAST, PRYGN211085CAST), Beca Grupo de Trabajo "Oncología" AEG
(Asociación Española de Gastroenterología), Fundación Privada Olga Torres, FP7 CHIBCHA

- 1073 Consortium, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR, Generalitat de
- 1074 Catalunya, 2014SGR135, 2014SGR255, 2017SGR21, 2017SGR653, 2021SGR00716,
- 1075 2021SGR01185), Catalan Tumour Bank Network (Pla Director d'Oncologia, Generalitat de
- 1076 Catalunya), PERIS (SLT002/16/00398, Generalitat de Catalunya), Marató TV3 (202008-10),
- 1077 CERCA Programme (Generalitat de Catalunya) and COST Actions BM1206 and CA17118.
- 1078 CIBERehd is funded by the Instituto de Salud Carlos III.ESTHER/VERDI. This work was
- 1079 supported by grants from the Baden-Württemberg Ministry of Science, Research and Arts and
- 1080 the German Cancer Aid.
- 1081 Harvard cohorts: HPFS is supported by the National Institutes of Health (P01 CA055075, UM1
- 1082 CA167552, U01 CA167552, R01 CA137178, R01 CA151993, and R35 CA197735), NHS by the
- 1083 National Institutes of Health (P01 CA087969, UM1 CA186107, R01 CA137178, R01 CA151993,
- 1084 and R35 CA197735), and PHS by the National Institutes of Health (R01 CA042182).
- 1085 Hawaii Adenoma Study: NCI grants R01 CA072520.
- HCES-CRC: the Hwasun Cancer Epidemiology Study–Colon and Rectum Cancer (HCES-CRC;
 grants from Chonnam National University Hwasun Hospital, HCRI15011-1).
- 1088 Kentucky: This work was supported by the following grant support: Clinical Investigator Award 1089 from Damon Runyon Cancer Research Foundation (CI-8); NCI R01CA136726.
- 1090 LCCS: The Leeds Colorectal Cancer Study was funded by the Food Standards Agency and
- 1091 Cancer Research UK Programme Award (C588/A19167).
- 1092 MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS
- 1093 was further supported by Australian NHMRC grants 509348, 209057, 251553 and 504711 and
- 1094 by infrastructure provided by Cancer Council Victoria. Cases and their vital status were
- 1095 ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health
- and Welfare (AIHW), including the National Death Index and the Australian Cancer Database.
- 1097 BMLynch was supported by MCRF18005 from the Victorian Cancer Agency.
- 1098 MEC: National Institutes of Health (R37 CA054281, P01 CA033619, and R01 CA063464).
- 1099 MECC: This work was supported by the National Institutes of Health, U.S. Department of Health
- 1100 and Human Services (R01 CA081488, R01 CA197350, U19 CA148107, R01 CA242218, and a
- 1101 generous gift from Daniel and Maryann Fong.

- 1102 MSKCC: The work at Sloan Kettering in New York was supported by the Robert and Kate
- 1103 Niehaus Center for Inherited Cancer Genomics and the Romeo Milio Foundation. Moffitt: This
- 1104 work was supported by funding from the National Institutes of Health (grant numbers R01
- 1105 CA189184, P30 CA076292), Florida Department of Health Bankhead-Coley Grant 09BN-13,
- 1106 and the University of South Florida Oehler Foundation. Moffitt contributions were supported in
- 1107 part by the Total Cancer Care Initiative, Collaborative Data Services Core, and Tissue Core at
- 1108 the H. Lee Moffitt Cancer Center & Research Institute, a National Cancer Institute-designated
- 1109 Comprehensive Cancer Center (grant number P30 CA076292).
- 1110 NCCCS I & II: We acknowledge funding support for this project from the National Institutes of1111 Health, R01 CA066635 and P30 DK034987.
- 1112 NFCCR: This work was supported by an Interdisciplinary Health Research Team award from
- 1113 the Canadian Institutes of Health Research (CRT 43821); the National Institutes of Health, U.S.
- 1114 Department of Health and Human Serivces (U01 CA074783); and National Cancer Institute of
- 1115 Canada grants (18223 and 18226). The authors wish to acknowledge the contribution of
- 1116 Alexandre Belisle and the genotyping team of the McGill University and Génome Québec
- 1117 Innovation Centre, Montréal, Canada, for genotyping the Sequenom panel in the NFCCR
- 1118 samples. Funding was provided to Michael O. Woods by the Canadian Cancer Society
- 1119 Research Institute.
- 1120 NSHDS: The research was supported by Biobank Sweden through funding from the Swedish
- 1121 Research Council (VR 2017-00650, VR 2017-01737), the Swedish Cancer Society (CAN
- 1122 2017/581), Region Västerbotten (VLL-841671, VLL-833291), Knut and Alice Wallenberg
- 1123 Foundation (VLL-765961), and the Lion's Cancer Research Foundation (several grants) and
- 1124 Insamlingsstiftelsen, both at Umeå University.
- OSUMC: OCCPI funding was provided by Pelotonia and HNPCC funding was provided by theNCI (CA016058 and CA067941).
- 1127 PLCO: Intramural Research Program of the Division of Cancer Epidemiology and Genetics and
- supported by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH,
- 1129 DHHS. Funding was provided by National Institutes of Health (NIH), Genes, Environment and
- 1130 Health Initiative (GEI) Z01 CP 010200, NIH U01 HG004446, and NIH GEI U01 HG 004438.
- SEARCH: The University of Cambridge has received salary support in respect of PDPP fromthe NHS in the East of England through the Clinical Academic Reserve. Cancer Research UK

- (C490/A16561); the UK National Institute for Health Research Biomedical Research Centres atthe University of Cambridge.
- 1135 SELECT: Research reported in this publication was supported in part by the National Cancer
- 1136 Institute of the National Institutes of Health under Award Numbers U10 CA037429 (CD Blanke),
- and UM1 CA182883 (CM Tangen/IM Thompson). The content is solely the responsibility of the
- 1138 authors and does not necessarily represent the official views of the National Institutes of Health.
- 1139 SMS and REACHS: This work was supported by the National Cancer Institute (grant P01
- 1140 CA074184 to J.D.P. and P.A.N., grants R01 CA097325, R03 CA153323, and K05 CA152715 to
- 1141 P.A.N., and the National Center for Advancing Translational Sciences at the National Institutes
- 1142 of Health (grant KL2 TR000421 to A.N.B.-H.)
- 1143 The Swedish Low-risk Colorectal Cancer Study: The study was supported by grants from the
- 1144 Swedish research council; K2015-55X-22674-01-4, K2008-55X-20157-03-3, K2006-72X-20157-
- 1145 01-2 and the Stockholm County Council (ALF project).
- 1146 Swedish Mammography Cohort and Cohort of Swedish Men: This work is supported by the
- 1147 Swedish Research Council /Infrastructure grant, the Swedish Cancer Foundation, and the
- 1148 Karolinska Institute's Distinguished Professor Award to Alicja Wolk.
- 1149 UK Biobank: This research has been conducted using the UK Biobank Resource under
- 1150 Application Number 8614
- 1151 VITAL: National Institutes of Health (K05 CA154337).
- 1152 The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes
- of Health, U.S. Department of Health and Human Services through contracts 75N92021D00001,
- 1154 **75N92021D00002**, **75N92021D00003**, **75N92021D00004**, **75N92021D00005**



Causal/confounded

causal/confounded

Causal

Lipop otem inputs Total-C C C VLDL-C IDL-C IDL-C IDL-C HDL-C HDL-C IDD-C IDD-C Apolipoproteins ApoB IDD-C IDD-C Fatty acids Total fatty acids IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C Fatty acid ratios Omega-6 IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C IDD-C <th>Lipoprotein lipi</th> <th></th> <th>!</th> <th></th> <th></th> <th></th>	Lipoprotein lipi		!			
LDL-CImage: constraint of the sector of the sec			i i	1	-	-0
HDL-C Image: Sector of the sector of th						0 -
Triglycerides Apolipoproteins ApoB Image: Sector Sec			i I	1		0—
Apolipoproteins ApoB Image: Sector Sect			1			o-
ApoA1 ApoA1 ApoBApoA ApoB/ApoA ApoB/ApoA ApoB/ApoA Fatty acids Total fatty acids ApoB/ApoA ApoB/ApoA Fatty acids Omega-3 Image ApoA Image ApoA Omega-6 Image ApoA Image ApoA Image ApoA PUFA Image ApoA Image ApoA Image ApoA PUFA Image ApoA Image ApoA Image ApoA MUFA Image ApoA Image ApoA Image ApoA MUFA Image ApoA Image ApoA Image ApoA MUFA Image ApoA Image ApoA Image ApoA Omega-6 Morga-3 % Image ApoA Image ApoA Image ApoA PUFA MUFA % Image ApoA Image ApoA Image ApoA PUFA/MUFA Image ApoA Image ApoA Image ApoA PUFA/MUFA Image ApoA Image ApoA Image ApoA Amino acids Alanine Image ApoA Image ApoA Isoleucine Image ApoA Image ApoA Image ApoA Isoleucine Image ApoA Image ApoA Image ApoA Thenylalanine <th></th> <th></th> <th>i</th> <th>1</th> <th></th> <th>≻</th>			i	1		≻
ApoB/ApoA Image: Statuse of the sta	Apolipoprotein	•	1			~
Fatty acids Total fatty acids ● Omega-3 Omega-6 ● PUFA ● ● MUFA ● ● MUFA ● ● DHA ● ● DHA ● ● Fatty acid ratios Omega-3% ● ● Omega-6% ● ● ● PUFA% ● ● ● PUFA% ● ● ● Omega-6% ● ● ● DHA % ● ● ● ● DHA % ● <			i i			o
Omega-3 Omega-6 Imaga-6 PUFA Imaga-6 PUFA Imaga-6 MUFA Imaga-6 SFA Imaga-6 DHA Imaga-6 Omega-6% Imaga-6 Omega-6% Imaga-6 Omega-6% Imaga-6 Omega-6% Imaga-6 PUFA Imaga-6 MUFA % Imaga-6 PUFA Imaga-6 PUFA Imaga-6 DHA Imaga-6 PUFA/MUFA Imaga-6 DHA % Imaga-6 Bisoleucine Imaga-6 Isoleucine Imaga-6 Phenylalanine Imaga-6 Total BCAA <th></th> <th>ApoB/ApoA</th> <th></th> <th>1</th> <th>-</th> <th><u>~</u></th>		ApoB/ApoA		1	-	<u>~</u>
Omega-6Image for the second secon	Fatty acids	Total fatty acids	I I	1		0 –
PUFAImage: constraint of the sector of the sect		Omega-3			1	-
MUFAImage: state of the state of		Omega-6		1		-
SFAImage: SFAImag		PUFA				<u> </u>
DHA Image S Image S Fatty acid ratios Omega-3% Image S Omega-6% Image S Image S PUFA % Image S Image S PUFA % Image S Image S MUFA % Image S Image S MUFA % Image S Image S DHA % Image S Image S Omega-6/Omega-3 Image S Image S Glycine Image S Image S Isoleucine Image S Image S Leucine Image S Image S Phenylalanine Image S Image S Total BCAA Image S Image S Glycolysis metabolites Glucose S Image S Image S Image S Image S<		MUFA				}_
Fatty acid ratios Omega-3 % Image -6 % Image -		SFA	I I			0 —
Omega-6 %Image of the second seco		DHA				
PUFA % ··· MUFA % ··· MUFA % ··· SFA % ··· DHA % ··· PUFA/MUFA ··· Omega-6/Omega-3 ··· Glycine ··· Glycine ··· Isoleucine ··· Leucine ··· Valine ··· Phenylalanine ··· Total BCAA ··· Glycolysis metabolites Glucose Lactate ··· Fluid balance Creatinine Albumin ···	Fatty acid ratios	Omega-3 %	i I	 	I I	
MUFA %···SFA %···DHA %···DHA %···PUFA/MUFA···Omega-6/Omega-3···Amino acidsAlanineGlycine···Glycine···Isoleucine···Isoleucine···Leucine···Phenylalanine···Tyrosine···Glycolysis metabolitesGlucoseLactate···Fluid balanceCreatinineAlbumin···<		Omega-6 %			- -	-
SFA % OHA %		PUFA %	I I	1		
DHA %Image: Constant of the sector of the sect		MUFA %			-0-	
PUFA/MUFA Image: Comega: Comega		SFA %	1	1		
Omega-6/Omega-3Image: Comega-6/Omega-3Amino acidsAlanineImage: Comega-6/Omega-3Amino acidsAlanineImage: Comega-6/Omega-3GlycineGlycineImage: Comega-6/Omega-3HistidineImage: Comega-6/Omega-3Image: Comega-6/Omega-3HistidineImage: Comega-6/Omega-7Image: Comega-6/Omega-7IsoleucineImage: Comega-7Image: Comega-7ValineImage: Comega-7Image: Comega-7Glycolysis metabolitesGlucoseImage: Comega-7Fluid balanceCreatinineImage: Comega-7AlbuminImage: Comega-7Image: Comega-7 <t< th=""><th></th><th>DHA %</th><th>l l</th><th>1</th><th>I I</th><th></th></t<>		DHA %	l l	1	I I	
Amino acids Alanine Image: Constraint of the sector o		PUFA/MUFA		1		- o -
Glycine Glycine Histidine Isoleucine Leucine Valine Tyrosine Glucose Total BCAA Glucose Lactate Creatinine Creatinine Albumin Albumin Isoleucine Albumin Isoleucine I		Omega-6/Omega-3			-	
Histidine Isoleucine Leucine Valine Phenylalanine Tyrosine Total BCAA Glycolysis metabolites Glucose Lactate Fluid balance Creatinine Albumin	Amino acids	Alanine	1		—o —	+
Isoleucine Isoleucine Leucine Valine Valine Isoleucine Tyrosine Glucose Glucose Creatinine Creatinine Creatinine Albumin Isoleucine		Glycine				-
Leucine Valine Valine Phenylalanine Tyrosine Glucose Glycolysis metabolites Glucose Lactate Albumin Albumin I and		Histidine				-
Valine Phenylalanine Tyrosine Total BCAA Glycolysis metabolites Glucose Lactate Fluid balance Creatinine Albumin		Isoleucine	I I		c	<u> </u>
Phenylalanine Tyrosine Total BCAA Glycolysis metabolites Glucose Lactate Fluid balance Creatinine Albumin		Leucine		1	. <u> </u>	o
Tyrosine		Valine		1		~
Total BCAA Image: matrix and matrix		Phenylalanine	i i	1		—
Glycolysis metabolites Glucose		Tyrosine			. — •	—
Lactate O Fluid balance Creatinine Albumin O		Total BCAA	i	1		
Lactate Image: Creatinine Albumin	Glycolvsis meta	bolites Glucose		1		
Albumin				1	-0	
Albumin	Fluid balance	Creatinine		i I I	 	0 —
Inflammation Glycoprotein acetyls		Albumin	1		—o —	-
	Inflammation	Glycoprotein acetyls	1	1	-	-
0.3 0.5 0.7 1.0		-	0.3	0.5	0.7 1	.0 2.
Beta (95% CI)						

					1
Lipoprotein lipi				—	1
	VLDL-C			-	
	LDL-C				
	HDL-C		-	•	
	Triglycerides		-	~	
Apolipoprotein				- o -	
	ApoA1				
	ApoB/ApoA		-	o -	
Fatty acids	Total fatty acids			-	-
	Omega-3				
	Omega-6			-	
	PUFA			— •	
	MUFA			o	1
	SFA				
	DHA			o	
Fatty acid ratios	Omega-3 %			o	
	Omega-6 %		-0-		
	PUFA %				
	MUFA %		o		- - -
	SFA %			-o-	
	DHA %			o	-
	PUFA/MUFA			•	1
	Omega-6/Omega-3		- 0		1
Amino acids	Alanine		-0-		1
	Glycine		-	-	
	Histidine		-	o -	1
	Isoleucine		-	-	1
	Leucine		-0		
	Valine		-	- :	1
	Phenylalanine		-	- :	
	Tyrosine		-	o-	
	Total BCAA		-	- :	1
Glycolysis meta	bolites Glucose		-	o -	
	Lactate		-0	-	1
Fluid balance	Creatinine		-0-		
	Albumin		-	o -	
Inflammation	Glycoprotein acetyls			~	
		-0	.1 0	.0 0	1 0.2
				ta (95% CI)	

Beta (95% CI)

Lipoprotein lipids					_	
	Total-C			1	I I	
	VLDL-C				i	
	LDL-C	_		-	i i	
	HDL-C		<u>}</u>			
	Triglycerides					
Apolipoproteins	ApoB					
	ApoA1					
	ApoB/ApoA					
Fatty acids	otal fatty acids			1		• 8y
	Omega-3	-				• 16y
	Omega-6			1		• 18y
	PUFA			1	 	• 25y
	MUFA			1		
	SFA	_		1	1	
	DHA		0		1	
Fatty acid ratios	Omega-3 %	_			1	
	Omega-6 %		<u> </u>			
	PUFA %					
	MUFA %		<u> </u>			
	SFA %		8			
	DHA %	=				
Amino acids	Alanine		<u> </u>	1		
	Histidine					
	Isoleucine			 		
	Leucine					
	Valine			1		
I	Phenylalanine		<u> </u>	1		
	Tyrosine	0	o	 	 	
Glycolysis metabolites	Glucose			1		
	Lactate				1	
Fluid balance	Creatinine					
	Albumin					
Inflammation Glycop	orotein acetyls					
		-0.1 0	.0	0.1	0.2	
			Beta (95%	CI)		